WCIRDC 2025 Resource Hub –
Welcome to our resource hub for WCIRDC 2025! This is a one-stop-shop for all your WCIRDC 2025 needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.
Table of Contents []
Useful Conference Links
- Conference Website
- Conference Registration
- Conference Program
- Day-by-day Conference Preview
- Conference Scientific Committee
Day-of Conference Reports
Top Highlights
- Back to basics: Insulin resistance as a foundational defect in T2D pathogenesis
- “Pre-prediabetes”: The association between insulin resistance and cardiometabolic risk in people without obesity
- Beyond glycemic management: Visceral adiposity as a therapeutic target for HFpEF
- Cardiovascular prevention: Dr. Nathan Wong discusses the role of risk scores, coronary calcium and opportunistic testing for cardiometabolic disease
- Combination therapies for CKD and T2D: Dr. Jennifer Green spotlights clinical insights from the phase 2 CONFIDENCE trial
- Expanding real-world cardiometabolic care: Dr. Pam Taub on the potential of imaging
- Dr. Jorge Plutzky explains the role of angiogenesis on cardiometabolic health
- Transforming diabetes care through AI‑driven insulin models, decision support, and digital prevention
- Mechanistic impacts that may explain how body weight reduction improves metabolic function in the eyes of Dr. Samuel Klein
- The role of the duodenum in metabolic dysfunction by Dr. Richard Pratley
- Dr. Richard Pratley on Evoke trial results, muscle loss, and geriatric diabetes care
- Bayer’s Kerendia (finerenone) improves morbidity and mortality in people with T2D in people with either CKD or HF, irrespective of baseline A1c in a pooled analysis
- Liver and obesity: From shared pathogenesis to screening and management by Drs. Jennifer Green, Robert Kushner, and Amreen Dinani
- Dr. Brian Feldman explains moving beyond lifestyle interventions to harness thermogenic fat in pediatric obesity
- Cortisol: The “forgotten hormone” and the potential underlying factor that impacts insulin resistance
- In utero exposure to maternal hyperglycemia and genetic risk independently increase T2D risk in adolescents, according to the HAPO study
- Dr. Yehuda Handelsman on hypertension and lipid management
- Leptin and endotrophin as dual pillars of fibro-inflammation in cardiometabolic disease
- Dr. Ralph DeFronzo on emerging therapies for beta cell regeneration and insulin sensitization
- From the eyes of a cardiologist: Perspectives on healthy diets in cardiometabolic health for obesity management
- Pipeline updates from Zealand: Advancing amylin innovation and diversifying cardiometabolic therapies
- Pipeline updates from Novo Nordisk: Expanding incretin leadership and diversifying into inflammation and beyond
- Pipeline updates from AstraZeneca: Addressing root cause of cardiometabolic disease
- The role of the liver in the cardiovascular-kidney-metabolic syndrome
- Peripheral artery disease in T2D: A modern epidemic of fragmented care
- CVOTs in 2025 for heart failure, lipid management, and hypertension
- Reframing hypercortisolism in T2D: Insights from the CATALYST trial from Dr. John Buse
- Gerald Reaven Award Lecture: Dr. Tracey McLaughlin details pathophysiology behind obesity and metabolic dysfunction
- Dr. Sunder Mudaliar explores the “incretin jungle” from GIP paradox to emerging agents
- CGM in prediabetes: Sensor variability and the need for new standards
- Obesity burden and CGM benefits in people with T1D
- Medical management of HFmrEF and HFpEF with rapid sequence or simultaneous initiation of SGLT-2 inhibitors, nsMRAs, and GLP-1 RAs